Drug
Sodium phenylbutyrate and taurursodiol clinical trials
Also written AMX0035.
- studies test it
- 10
- open now
- 1
- in phase 3
- 4
- first study started
- 2017
Keep track of what changes. Save the sodium phenylbutyrate and taurursodiol studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
- AMX0035
- 10
Studies by the year they started
10 studies that test it; most in 2018 (2)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2018 | 2 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 1
- Phase 2
- 8
- Phase 3
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 9 · Other 1
Amylyx Pharmaceuticals Inc. (9) · University of Washington (1)
Studies
Open first, then newest update. How each study uses sodium phenylbutyrate and taurursodiol is read from its arms, and is right about nine times in ten.
Testing it · 10
- METabolic MODulation to Enhance Insulin Sensitivity and Mitochondrial Function in Type 1 Diabetes (MetMod-T1D)RecruitingPhase 2University of WashingtonNCT07699380Written as AMX0035
- AMX0035 and Progressive Supranuclear PalsyCompletedPhase 2/3Amylyx Pharmaceuticals Inc.NCT06122662Written as AMX0035
- AMX0035 in Adult Patients With Wolfram SyndromeActive, not recruitingPhase 2Amylyx Pharmaceuticals Inc.NCT05676034Written as AMX0035
- Open Label Extension Study of AMX0035 in Patients With ALSCompletedPhase 2Amylyx Pharmaceuticals Inc.NCT03488524Written as AMX0035
- Study to Assess the Safety and Biological Activity of AMX0035 for the Treatment of Alzheimer's DiseaseCompletedPhase 2Amylyx Pharmaceuticals Inc.NCT03533257Written as AMX0035
- Extension Study Evaluating The Safety And Tolerability of AMX0035CompletedPhase 3Amylyx Pharmaceuticals Inc.NCT05619783Written as AMX0035
- Phase III Trial of AMX0035 for Amyotrophic Lateral Sclerosis TreatmentActive, not recruitingPhase 3Amylyx Pharmaceuticals Inc.NCT05021536Written as AMX0035
- AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)CompletedPhase 2Amylyx Pharmaceuticals Inc.NCT03127514Written as AMX0035
- Pharmacokinetic and Pharmacodynamic Study of AMX0035 in Patients With ALSActive, not recruitingPhase 1/2Amylyx Pharmaceuticals Inc.NCT04987671Written as AMX0035
- A Compassionate Use Protocol of AMX0035 for Treatment of Patients With Amyotrophic Lateral Sclerosis (ALS)CompletedPhase 2/3Amylyx Pharmaceuticals Inc.NCT04516096Written as AMX0035
Codes
What other systems call sodium phenylbutyrate and taurursodiol · ClinicalTrials.gg INT001980
- MeSH (NLM) C000723627sodium phenylbutyrate and taurursodiolOne source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000723627 | sodium phenylbutyrate and taurursodiol | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.